Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer

Cancer Letters

Volumn 268, Issue 2, 2008, Pages 340-347

  Das, Kakoli ^a   Cheah, Peh Yean ^a   Lim, Pei Li ^a   Zain, Yasmin Bte Mohad ^a   Stephanie, Fook Chong ^a   Zhao, Yi ^a   Cheng, Christopher ^a   Lau, Weber ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Androgen receptor; CAG repeats; CYP17; Polymorphism; Prostate cancer; PSA; SRD5A2

Indexed keywords

ADENINE; ANDROGEN RECEPTOR; CYTOCHROME P450C17; CYTOCHROME P450C17ALPHA; CYTOSINE; GUANINE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; RISK REDUCTION; TRINUCLEOTIDE REPEAT;

ADULT; AGED; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEATS;

EID: 48749084780     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.04.009     Document Type: Article

References (42)

1. Hsing A.W., Gao Y.T., Wu G., et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60 (2000) 5111-5116
2. A. Seow, W.P. Koh, K.S. Chia, L.M. Shi, H.P. Lee, R. Shanmugaratnam, Trends in Cancer Incidence in Singapore 1968-2002, Singapore Cancer Registry No. 6 (2004) 128-129.
3. Hakimi J.M., Rondinelli R.H., Schoenberg M.P., and Barrack E.R. Androgen-receptor gene structure and function in prostate cancer. World J. Urol. 14 5 (1996) 329-337
4. Lunn R.M., Bell D.A., Mohler J.L., and Taylor J.A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20 9 (1999) 1727-1731
5. Gsur A. Genetic polymorphisms and prostate cancer risk. World J. Urol. 21 (2004) 414-423
6. Lubhan D.B., Joseph D.R., Sar M., et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in the prostate. Mol. Endocrinol. 2 (1988) 1265-1275
7. Stamey T.A. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317 (1987) 909-916
8. Xue W.M., Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A., and Ingles S.A. Susceptibility to prostrate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res. 60 (2000) 839-841
9. Bratt O., Borg A., Kristoffersson U., Lundgren R., Zhang Q.X., and Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer 81 (1999) 672-676
10. Beilin J., Harewood L., Frydenberg M., et al. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer 92 (2001) 941-949
11. Hardy D.O., Scher H.I., Bogenreider T., et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab. 81 12 (1996) 4400-4405
12. Stanford J.L., Just J.J., Gibbs M., et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57 (1997) 1194-1198
13. Giovannucci E., Platz E.A., Stampfer M.J., et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology 53 (1999) 121-125
14. Mitsumori K., Terai A., Oka H., et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate 41 4 (1999) 253-257
15. Roberts R.O., Bergstralh E.J., Cunningham J.M., et al. Androgen receptor polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am. J. Epidemiol. 159 (2004) 269-276
16. Reigman P.H., Vlietstra R.J., van der Korput J.A., et al. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 5 12 (1991) 1921-1930
17. Cramer S.D., Chang B.L., Rao A., et al. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J. Natl. Cancer Inst. 95 14 (2003) 1044-1053
18. Rao A., and Cramer S.D. Identification of a polymorphism in the ARE 1 region of the PSA promoter. Proc. Am. Assoc. Cancer Res. 40 (1999) 65
19. Thigpen A.E., Davis D.L., Milatovich A., et al. Molecular genetics of steroid 5α-reductase 2 deficiency. J. Clin. Invest. 90 3 (1992) 799-809
20. Thigpen A.E., Silver R.I., Guileyardo J.M., et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J. Clin. Invest. 92 2 (1993) 903-910
21. Reichardt J.K., Makridakis N., Henderson B.E., et al. Genetic variability of the human SRD5A2 gene: implications for Prostate Cancer risk. Cancer Res. 55 (1995) 3973-3975
22. Makridakis N., Ross R.K., Pike M.C., et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 57 6 (1997) 1020-1022
23. Febbo P.G., Knatoff P.W., Platz E.A., et al. The V89L polymorphism in the 5 alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res. 59 23 (1999) 5878-5881
24. Nam R.K., Toi A., Vesprini D., et al. V89L polymorphism of type 2, 5 alpha-reductase enzyme gene predicts prostate cancer presence and progression. Urology 57 1 (2001) 199-204
25. Makridakis N., Ross R.K., Pike M.C., et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354 (1999) 975-978
26. Jaffe J.M., Malkowicz S.B., Walker A.H., et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 60 (2000) 1626-1630
27. Salam M.T., Ursin G., Skinner E.C., Dessissa T., and Reichardt J.K. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol. Oncol. 23 4 (2005) 246-253
28. Roberts R.O., Bergstralh E.J., Farmer S.A., et al. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH. Prostate 62 4 (2005) 380-387
29. Gsur A., Bernhofer G., Hinteregger S., et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int. J. Cancer 87 3 (2000) 434-437
30. Madigan M.P., Gao Y.T., Deng J., et al. CYP 17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int. J. Cancer 107 (2003) 271-275
31. Giovanucci E., Stampfer M.J., Krithivas K., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA 94 (1997) 3320-3323
32. Irvine R.A., Yu M.C., Ross R.K., and Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55 (1995) 1937-1940
33. Correa-Cerro L., Wohr G., Haussler J., et al. (CAG) nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur. J. Hum. Genet. 7 (1999) 357-362
34. Medeiros R., Morais A., Vasconcelos A., et al. Linkage between polymorphisms in the prostate-specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53 1 (2002) 88-94
35. Gsur A., Preyer M., Haidinger G., et al. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23 (2002) 1647-1651
36. Chiang C.H., Chen K.K., Chang L.S., and Hong C.J. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer. J. Urol. 171 (2004) 1529-1532
37. Xue W.M., Coetzee G.A., Ross R.K., et al. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 575-579
38. Cicek M.S., Conti D.V., Curran A., et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17 and the AR. Prostate 59 (2004) 69-76
39. Shibata A., Garcia M.I., Cheng I., et al. Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 52 (2002) 269-272
40. Soderstrom T., Wadelius M., Andersson S.O., et al. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12 4 (2002) 307-312
41. Ntais C., Polycarpou A., and Ioannidis J.P. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 120-126
42. Beebe-Dimmer J.L., Lange L.A., Cain J.E., et al. Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. Prostate Cancer Prostatic Dis. 9 1 (2006) 50-55